Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 3
2009 5
2010 5
2011 5
2012 3
2013 6
2014 5
2015 5
2016 11
2017 6
2018 9
2019 5
2020 11
2021 22
2022 16
2023 16
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
MDM2 inhibition: an important step forward in cancer therapy.
Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J, Andreeff M. Konopleva M, et al. Among authors: papayannidis c. Leukemia. 2020 Nov;34(11):2858-2874. doi: 10.1038/s41375-020-0949-z. Epub 2020 Jul 10. Leukemia. 2020. PMID: 32651541 Review.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Rambaldi A, Ritchie EK, Papayannidis C, Tuglus CA, Morris JD, Stein A. Martinelli G, et al. Among authors: papayannidis c. Eur J Cancer. 2021 Mar;146:107-114. doi: 10.1016/j.ejca.2020.12.022. Epub 2021 Feb 13. Eur J Cancer. 2021. PMID: 33588145 Free article. Clinical Trial.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, Ommen H, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin V, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, DiNardo CD. de Botton S, et al. Among authors: papayannidis c. Blood. 2023 Jan 12;141(2):156-167. doi: 10.1182/blood.2021014901. Blood. 2023. PMID: 35714312 Free PMC article. Clinical Trial.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G; AVALON Cooperative Group. Todisco E, et al. Among authors: papayannidis c. Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24. Cancer. 2023. PMID: 36692409 Free article.
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón JA, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE. Heuser M, et al. Among authors: papayannidis c. Ann Hematol. 2021 May;100(5):1181-1194. doi: 10.1007/s00277-021-04465-4. Epub 2021 Mar 19. Ann Hematol. 2021. PMID: 33740113 Free PMC article. Clinical Trial.
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A. Martinelli G, et al. Among authors: papayannidis c. J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29. J Clin Oncol. 2017. PMID: 28355115 Free article. Clinical Trial.
Acute Myeloid Leukemia Mutations: Therapeutic Implications.
Papayannidis C, Sartor C, Marconi G, Fontana MC, Nanni J, Cristiano G, Parisi S, Paolini S, Curti A. Papayannidis C, et al. Int J Mol Sci. 2019 Jun 3;20(11):2721. doi: 10.3390/ijms20112721. Int J Mol Sci. 2019. PMID: 31163594 Free PMC article. Review.
Editorial: Precision medicine for acute myeloid leukemia.
Marconi G, Guolo F, Nanni J, Papayannidis C. Marconi G, et al. Among authors: papayannidis c. Front Oncol. 2023 Jul 25;13:1233757. doi: 10.3389/fonc.2023.1233757. eCollection 2023. Front Oncol. 2023. PMID: 37560469 Free PMC article. No abstract available.
Blinatumomab in Ph+ B-ALL: present and perspectives.
Papayannidis C, Martinelli G. Papayannidis C, et al. Oncotarget. 2017 Oct 25;8(55):93309-93310. doi: 10.18632/oncotarget.22071. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212147 Free PMC article. No abstract available.
124 results